RGNX  valuation analysis

Basics
Name: REGENXBIO Inc
Description: REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 05, 2021
Market cap: $1.53B (1135th)
Sales(TTM): $155.81M (1374th)
Earnings(TTM): -$121.35M (1273rd)

Value
FFER: 0.91 (why)
Actual price: $35.97
FFEThis is REGENXBIO Inc's the estimated price. FFEs are the denominator of the FFER ratio.: $39.59
Quantile: RGNX is cheap given its fundamentals.
Prices as of EOD 2021-07-15
Price & Estimates
Sales & Earnings history (TTM)
Notable
  • REGENXBIO Inc's sales grew by 199.7% ($51.99M to $155.81M) over one year against a market average growth of 20.1%.
Earnings / MarketCap
REGENXBIO Inc
"Biotechnology" industry
Sales / MarketCap
REGENXBIO Inc
"Biotechnology" industry
Book / MarketCap
REGENXBIO Inc
"Biotechnology" industry
Equity / Assets
REGENXBIO Inc
"Biotechnology" industry